MARKET

IBIO

IBIO

Ibio
NASDAQ
2.430
+0.050
+2.10%
After Hours: 2.420 -0.01 -0.41% 19:50 03/11 EDT
OPEN
2.380
PREV CLOSE
2.380
HIGH
2.515
LOW
2.310
VOLUME
896.73K
TURNOVER
--
52 WEEK HIGH
5.85
52 WEEK LOW
0.5562
MARKET CAP
83.94M
P/E (TTM)
-1.9303
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
TipRanks · 2d ago
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
TipRanks · 2d ago
iBio Reports Early Study Results Showing Experimental Obesity Drug Reduced Fat in Animals
Benzinga · 2d ago
IBIO REPORTS PRECLINICAL BODY COMPOSITION DATA FROM OBESE NON-HUMAN PRIMATES TREATED WITH IBIO-610, A POTENTIAL FIRST-IN-CLASS TREATMENT FOR FAT-SELECTIVE WEIGHT LOSS
Reuters · 2d ago
IBIO INC - IBIO-610 REDUCED VISCERAL FAT BY 6.7% AND TOTAL FAT MASS BY 5.2% IN NHP STUDY
Reuters · 2d ago
Weekly Report: what happened at IBIO last week (0302-0306)?
Weekly Report · 2d ago
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Ibio (IBIO)
TipRanks · 5d ago
iBio Price Target Announced at $7.00/Share by Jones Trading
Dow Jones · 03/03 13:14
More
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.

Webull offers Ibio Inc stock information, including NASDAQ: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.